Derivatives of 3,3-diphenylpropylamines

Details Derivatives of 3,3-diphenylpropylamines Derivatives of 3,3-diphenylpropylamines

2007-06-12

2007-06-12

Tucker, Zachary C. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S648000, C560S194000, C564S316000

Reexamination Certificate

active

10766263

ABSTRACT:
The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

REFERENCES:
patent: 2556636 (1951-06-01), Sperber et al.
patent: 2567245 (1951-09-01), Sperber at al.
patent: 2676964 (1954-04-01), Sperber et al.
patent: 3261841 (1966-07-01), Zenitz
patent: 3446901 (1969-05-01), Macclesfield
patent: 4988730 (1991-01-01), Korbonits et al.
patent: 5382600 (1995-01-01), Jonsson et al.
patent: 5559269 (1996-09-01), Johansson et al.
patent: 5686464 (1997-11-01), Johansson et al.
patent: 5922914 (1999-07-01), Gage et al.
patent: 6310248 (2001-10-01), Andersson et al.
patent: 6313132 (2001-11-01), Johansson et al.
patent: 6517864 (2003-02-01), Orup Jacobsen et al.
patent: 6566537 (2003-05-01), Andersson et al.
patent: 6630162 (2003-10-01), Nilvebrant et al.
patent: 6689916 (2004-02-01), Andersson et al.
patent: 6713464 (2004-03-01), Meese et al.
patent: 6770295 (2004-08-01), Kreilgard et al.
patent: 6783769 (2004-08-01), Arth et al.
patent: 6809214 (2004-10-01), Meese
patent: 6809225 (2004-10-01), Donsbach et al.
patent: 6858650 (2005-02-01), Meese
patent: 6890920 (2005-05-01), Richards et al.
patent: 6911217 (2005-06-01), Gren et al.
patent: 2003/0124179 (2003-07-01), Jacobsen et al.
patent: 2003/0152624 (2003-08-01), Aldrich et al.
patent: 2003/0158176 (2003-08-01), Richards et al.
patent: 2004/0064821 (2004-04-01), Rousselle
patent: 2004/0186061 (2004-09-01), Claus et al.
patent: 2005/0004223 (2005-01-01), Slatter et al.
patent: 830193 (1952-02-01), None
patent: 766207 (1952-12-01), None
patent: 925 468 (1955-03-01), None
patent: 1 216 318 (1966-05-01), None
patent: 325 571 (1989-07-01), None
patent: 667 852 (1995-08-01), None
patent: 831799 (1996-06-01), None
patent: 872233 (1997-04-01), None
patent: 948321 (1997-12-01), None
patent: 957073 (1998-05-01), None
patent: 1 019 358 (2000-07-01), None
patent: 1 077 912 (2001-02-01), None
patent: 1 128 819 (2001-09-01), None
patent: 624 117 (1949-05-01), None
patent: 627 139 (1949-07-01), None
patent: 685 696 (1953-01-01), None
patent: 689 835 (1953-04-01), None
patent: 690 274 (1953-04-01), None
patent: 692 931 (1953-06-01), None
patent: 1025041 (1964-02-01), None
patent: 1 169 944 (1969-11-01), None
patent: 1 169 945 (1969-11-01), None
patent: WO 89/06644 (1989-07-01), None
patent: WO 93/23025 (1993-11-01), None
patent: WO 94/11337 (1994-05-01), None
patent: WO 96/12477 (1996-05-01), None
patent: WO 98/03067 (1998-01-01), None
patent: WO 98/43942 (1998-10-01), None
patent: WO 98/56359 (1998-12-01), None
patent: WO 99/58478 (1999-11-01), None
patent: WO 00/12069 (2000-03-01), None
patent: WO 00/27364 (2000-05-01), None
patent: WO 01/34139 (2001-05-01), None
patent: WO 02/11702 (2002-02-01), None
patent: WO 02/089773 (2002-11-01), None
patent: WO 03/002059 (2003-01-01), None
patent: WO 03/007918 (2003-01-01), None
patent: WO 03/020241 (2003-03-01), None
patent: WO 03/021271 (2003-03-01), None
patent: WO 03/026564 (2003-04-01), None
patent: WO 03/035599 (2003-05-01), None
patent: WO 03/039464 (2003-05-01), None
patent: WO 03/063834 (2003-08-01), None
patent: WO 03/099268 (2003-12-01), None
patent: WO 03/103637 (2003-12-01), None
patent: WO 03/106421 (2003-12-01), None
patent: WO 04/019892 (2004-03-01), None
Nilvebrant et al.,European Journal of Pharmacology, 327(1997) pp. 195-207.
Nilvebrant et al.,Pharmacology and Toxicology, vol. 81, pp. 169-172, 1997.
Nilvebrant et al.,Life Sciences. vol. 60 (13/14), pp. 1129-1136, 1997.
Postlind et al.,Drug Metabolism and Disposition, vol. 26 (4), pp. 289-293, 1998.
Andersson et al.,Drug Metabolism and Disposition, vol. 26 (6), pp. 528-535, 1998.
Brynne et al.,J. Clin. Pharm. Ther., vol. 35 (7), pp. 287-295, 1997.
Lipinski, et al., “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings” Elsevier Advanced Drug Delivery Reviews vol. 23, pp. 3-25, 1997.
Netzer, et al., “Screening lead compounds for QT interval prolongation” Drug Discovery Today vol. 6, No. 2, pp. 78-84, Jan. 2001.
Nilvebrant & Sparf, “Differences between Binding Affinities of some Antimuscarinic Drugs in the parotid Gland and those in the Urinary Bladder and Ileum” Acta Pharmacol. et toxicol. vol. 53, No. 4, pp. 304-313, Oct. 1983.
Pharmacology/Toxicology Review from Application No. 21-518, Center for Drug Evaluation and Research, pp. 1-3. (2004).
Roy, et al., “HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine Terfenadine” Circulation vol. 94, No. 4, pp. 817-823, Aug. 15, 1996.
Abrams et al., “Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder,” 1998, Br. J. Urol. 81:801-810.
Anderson et al., “Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence,” 1999, J. Urol. 161:1809-1812.
Andersson et al., “Pharmacological treatment of urinary incontinence,” in Abrams P., Khoury S., Wein A. (Eds),Incontinence, 2nd International Consultation on Incontinence,Plymouth, Plymbridge Distributors Ltd, UK, Plymouth, 2002, pp. 479-511.
Andersson, “Antimuscarinics for treatment of overactive bladder,” 2004, Lancet Neurol. 3:46-53.
Andersson & Wein, “Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence,” 2004, Pharmacol. Rev. 56:581-631.
Appell et al., “Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study,” 2001, Mayo Clinic Proceedings 76:358-363.
Breidenbach et al., “Pharmacodynamic profiling of the novel antimuscarinic drug fesoterodine on rat bladder,” 2002, Proceedings of the International Continence Society, 32:449.
Brynne et al., Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine, 1998, Clin. Pharmacol Thera. 63:529-539.
Brynne et al., “Tolterodine does not Affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine, and omeprazole,” 1999, Br. J. Clin. Pharmacol. 47:145-150.
Brynne et al., “Fluoxetine inhibits the metabolism of tolterodine -pharmacokinetic implications and proposed clinical relevance,” 1999, Br. J. Clin. Pharmacol. 48:553-563.
Brynne et al., “Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity,” 1999, Br. J. Clin. Pharmacol. 48:564-572.
Cawello et al., “Multiple dose pharmacokinetics of fesoterodine in human subjects,” 2002, Nauyn-Schmiedeberg's Arch. Pharmacol. 365 (Suppl. 1):428, 2002.
Chancellor et al., “A comparsion of the effects on saliva output of oxybutynin chloride and tolterodine tartrate,” 2001, Clinical Therapeutics 23:753-760.
Chapple & Udo, “Delay to maximum effect in overactive bladder patients treated with oxybutynin tolterodine tartrate with oxybutynin or tolterodine,” 2000, European Urology 37(Suppl. 2):84, abstract 335 from the XVth Congress of the European Association of Urology, Brussels, Belgium, Apr. 12-15, 2000.
Chapple et al., “Fesoterdine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a Phase II controlled study,” 2004, Proceedings of the International Continence Society, 34:142.
Clemett & Jarvis, &#x

Affiliated with

Also associated with

Rating

Derivatives of 3,3-diphenylpropylamines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Derivatives of 3,3-diphenylpropylamines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of 3,3-diphenylpropylamines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3862671